SEC Tracker
Get the app

Dror Ortho-Design DROR

Dror Ortho-Design Q3 FY24: net loss $1.8M; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Dror Ortho-Design reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$1.8MAgainst −$554K in Q3 FY2310-Q income statement, on EDGAR
  2. Diluted EPS$0.00Against $0.00 in Q3 FY2310-Q income statement, on EDGAR
  3. Cash and cash equivalents$1.1M−72% from $4.0M in Q3 FY2310-Q balance sheet, on EDGAR
  4. Cash from operations−$691KAgainst −$1.7M in Q3 FY2310-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Dror Ortho-Design files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3843 and related industry codes: the same peer list as the financial tables.

  1. Neuraxis NRXS public float $20M, Jun 30, 2025
  2. Allurion Technologies ALUR public float $21M, Jun 30, 2025
  3. Positron POSC public float $22M, Jun 30, 2025
  4. Vivos Therapeutics VVOS public float $23M, Jun 30, 2025
  5. Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025